Prospects for Bayer’s oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
Moderna in talks with FDA over Phase 4 Covid vaccine data
Moderna said it’s working with US regulators to provide post-marketing data on its Covid-19 vaccines that could restore their use to a wider group after



